Sector News

Bayer CEO happy to have fair outcomes-based pricing

December 4, 2014
Life sciences
Outcomes-based pricing holds no fears for Marijn Dekkers but the Bayer chief executive has urged governments to level the playing field when comparing old drugs with innovative products.
 
At the German major’s Perspective on Innovation meeting in Leverkusen, Dr Dekkers (pictured) told PharmaTimes that in terms of realigning payment mechanisms around health outcomes is perfectly reasonable. “We are all for only getting paid for really good drugs,” he said, adding that as an innovative company “we have the ability to come up with treatments better than those on the market”.
 
Dr Dekkers went on to say “it is okay to be tested on that in the process of price-setting, that is fine, we should only be paid for the value we bring”. However he did add one important caveat.
 
He noted that in no other industry does a product’s price drop 80% when it goes off-patent, the key sticking-point when reimbursement issues come up. “When we have a new drug that is significantly better than the previous drug but the previous drug just went generic, we are compared to the 20% price, not the 100% price”.
 
Dr Dekkers said that when one uses the 20% (i.e. generic) price for comparisons, it is hard to show continuously improvement of new drugs even though they are significantly better than older ones. It is “a huge dilemma [and] if we don’t solve it we will take away the economic motivation” for high-risk innovative projects.
 
Volkswagen Beetle analogy
 
He then gave PharmaTimes an analogy with cars, saying that “if the automotive industry have patents like we have, we would all still be driving around in Volkswagen Beetles from the 60s. All the innovations and continuous improvements VW has made would not have justified the price differential”.
 
Dr Dekkers was upbeat at the meeting, noting that in the pharmaceuticals segment, Bayer has successfully completed 25 Phase III clinical studies since 2010 and emphasised the strength of its pipeline (more on this to follow on PharmaTimes).
 
He also highlighted the firm’s over-the-counter business, ranked number two in the world after acquiring the consumer care business of Merck & Co. When asked why an innovative company was focusing on OTC, Dr Dekkers said “we need diversifaction as a buffer…we don’t have to be sexy all the time, more selective sexiness”.
 
By Kevin Grogan
 
Source: Pharma Times

comments closed

Related News

May 21, 2022

As monkeypox cases emerge in US and Europe, Bavarian Nordic inks vaccine order

Life sciences

A monkeypox outbreak is emerging in the U.S. and Europe, and at least one country is amping up countermeasure preparedness. Bavarian Nordic has secured a contract with an unnamed European country to supply its smallpox vaccine, called Imvanex in Europe, in response to the emergence of monkeypox cases, the Danish company said Thursday.

May 21, 2022

Moderna chairman Afeyan defends hiring practices after CFO debacle: report

Life sciences

Moderna’s recent chief financial officer debacle—in which Jorge Gomez departed on his second day on the job—raised questions about the company’s hiring process given its rush to global biopharma prominence. The most obvious one: How was it possible for Gomez to be hired when he was under investigation by his previous employer, Dentsply Sirona of Charlotte, N.C.

May 21, 2022

Merck to pay up to $1.4B in cancer deal with Kelun, but details are scarce

Life sciences

Merck & Co. is plucking a cancer project from the branch of Chinese-based Kelun Pharmaceutical for up to $1.4 billion, but details from the New Jersey-based Big Pharma have been hard to come by. The deal, first disclosed Monday on the Shenzhen stock exchange, has Merck handing over $47 million in upfront cash in exchange for ex-China rights to a “macromolecular tumor project.”